XBiotech Croissance future

Future contrôle des critères 0/6

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Biotechs croissance des bénéfices	36.2%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

DB:4XB - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2024	N/A	-35	-25	-23	N/A
3/31/2024	N/A	-31	-22	-21	N/A
12/31/2023	N/A	-25	-19	-19	N/A
9/30/2023	0	-23	-19	-18	N/A
6/30/2023	2	-28	-19	-18	N/A
3/31/2023	4	-31	-15	-15	N/A
12/31/2022	4	-33	-15	-15	N/A
9/30/2022	8	-36	-14	-13	N/A
6/30/2022	11	-27	-17	-16	N/A
3/31/2022	14	-20	59	63	N/A
12/31/2021	18	-17	66	69	N/A
9/30/2021	19	-13	66	71	N/A
6/30/2021	25	-12	76	82	N/A
3/31/2021	36	-14	-7	-3	N/A
12/31/2020	44	-11	-69	-65	N/A
9/30/2020	39	677	-70	-69	N/A
6/30/2020	28	673	-82	-81	N/A
3/31/2020	13	674	-75	-74	N/A
12/31/2019	N/A	669	-18	-18	N/A
9/30/2019	N/A	-24	-20	-20	N/A
6/30/2019	N/A	-23	-19	-19	N/A
3/31/2019	N/A	-23	-18	-18	N/A
12/31/2018	N/A	-21	-17	-17	N/A
9/30/2018	N/A	-22	-19	-18	N/A
6/30/2018	N/A	-23	-21	-21	N/A
3/31/2018	N/A	-27	N/A	-25	N/A
12/31/2017	N/A	-33	N/A	-34	N/A
9/30/2017	N/A	-42	N/A	-40	N/A
6/30/2017	N/A	-49	N/A	-48	N/A
3/31/2017	N/A	-53	N/A	-48	N/A
12/31/2016	N/A	-53	N/A	-46	N/A
9/30/2016	N/A	-48	N/A	-44	N/A
6/30/2016	N/A	-47	N/A	-36	N/A
3/31/2016	N/A	-40	N/A	-37	N/A
12/31/2015	N/A	-37	N/A	-33	N/A
9/30/2015	N/A	-32	N/A	-26	N/A
6/30/2015	N/A	-28	N/A	-22	N/A
3/31/2015	N/A	-25	N/A	-16	N/A
12/31/2014	N/A	-22	N/A	-12	N/A
9/30/2014	N/A	-18	N/A	-11	N/A

XBiotech Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech Inc., Annual General Meeting, Jun 20, 2024

New major risk - Share price stability

Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke

Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

First half 2023 earnings released: US$0.41 loss per share (vs US$0.56 loss in 1H 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$1.08 loss per share (vs US$0.58 loss in FY 2021)

XBiotech Inc. Announces Executive Changes

Insufficient new directors

Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.17 loss in 2Q 2021)

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2000 Dynamic Index

XBiotech Announces Successful Completion of Phase I Portion of Pancreatic Cancer Study

XBiotech Inc., Annual General Meeting, Jun 22, 2022

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.087 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Insufficient new directors

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 2Q 2020)

XBiotech Inc. Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

New 90-day high: €17.10

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

New 90-day low: €13.80

Xbiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-Covid-19 Therapeutic Cocktail

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

New 90-day high - €16.04

New 90-day high - €15.29

New 90-day high - €15.07

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 3000 Growth Index

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance